zn-d5
Small moleculeexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 31, 2020 (NCT04500587)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Apoptosis regulator Bcl-2INHIBITOR
BCL2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05199337 | Phase 1/Phase 2 (Phase 2) | Nov 30, 2021 | Zentalis Pharmaceuticals |
| NCT05127811 | Phase 1 | Oct 21, 2021 | Zentera Therapeutics HK Limited |
| NCT04854174 | Phase 1 | Jun 4, 2021 | K-Group Beta |
| NCT04500587 | Phase 1 | Oct 31, 2020 | K-Group Beta |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| K-Group Beta | For profit | 2 | 2 | 1 | 2020 |
| Zentalis Pharmaceuticals | For profit | 1 | 1 | 1 | 2021 |
| Zentera Therapeutics HK Limited | For profit | 1 | 1 | 1 | 2021 |
3 organizations
Page 1 / 1